Holi Offer - Use Code HOLI24

Register Now

Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose

Published on June 05, 2022
Current Context: The Hyderabad-based company has come up with a booster dose of Corbevax that increased the neutralizing antibody titers in the Covishield and Covaxin groups significantly when compared to placebo.
Biological E's Corbevax gets DCGI nod as a Heterologous Covid Booster Dose
  • Recently the Drug Controller General of India (DCGI) approved Biological E’s Corbevax and it becomes the first vaccine to get to be used as a heterologous booster for adults who have either received two shots of Covaxin or Covishield.
  • As of now, India was using a homologous booster shot for all precaution doses. Now, this become the first heterologous booster for adults.
  • Corbevax shot can be booked through the Co-WIN portal by anyone who wished to take a shot.
  • Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.
  • Apart from that, it has been claimed that there were no severe or adverse events of interest for 3 months of follow-up after the booster dose was administered.
  • Homologous boosters increased neutralizing antibody titers by a factor of 4 to 20, whereas heterologous boosters increased titers by a factor of 6 to 73.

Question:

Q.1 DGCA approved Corbevax Booster is a __________type of booster which is used for adults?
a. Homologous
b. Heterologous
c. Mixed
d. Double strain booster
ebook store

About us

ramandeep singh

Ramandeep Singh is a seasoned educator and banking exam expert at BankExamsToday. With a passion for simplifying complex concepts, he has been instrumental in helping numerous aspirants achieve their banking career goals. His expertise and dedication make him a trusted guide in the journey to banking success.

  • Follow me:
Close Menu
Close Menu